Table 1 Clinicopathologic characteristics according to KRAS mutation status
From: The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
| Â | Patients with KRAS status | p-value | ||
|---|---|---|---|---|
Negative | Positive | Total | ||
(NÂ =Â 691) | (NÂ =Â 401) | (NÂ =Â 1092) | ||
Sex | Â | Â | Â | 0.001 |
 Male | 452 (65.4%) | 220 (54.9%) | 672 (61.5%) |  |
 Female | 239 (34.6%) | 181 (45.1%) | 420 (38.5%) |  |
Age | Â | Â | Â | 0.771 |
  < 50 year | 90 (13.0%) | 49 (12.2%) | 139 (12.7%) |  |
  ≥ 50 year | 601 (87.0%) | 352 (87.8%) | 953 (87.3%) |  |
Location | Â | Â | Â | <0.001 |
 Rt colon | 145 (21.0%) | 130 (32.4%) | 275 (25.2%) |  |
 Lt colon | 309 (44.7%) | 158 (39.4%) | 467 (42.8%) |  |
 Rectum | 221 (32.0%) | 107 (26.7%) | 328 (30.0%) |  |
 Multiple | 16 (2.3%) | 6 (1.5%) | 22 (2.0%) |  |
Stage | Â | Â | Â | 0.889 |
 Tis | 15 (2.2%) | 8 (2.0%) | 23 (2.1%) |  |
 StageI | 129 (18.8%) | 75 (18.8%) | 204 (18.8%) |  |
 StageII | 195 (28.3%) | 112 (28.0%) | 307 (28.2%) |  |
 StageIII | 256 (37.2%) | 142 (35.5%) | 398 (36.6%) |  |
 StageIV | 93 (13.5%) | 63 (15.8%) | 156 (14.3%) |  |
T stage | Â | Â | Â | 0.005 |
 T1 | 71 (10.5%) | 25 (6.4%) | 96 (9.0%) |  |
 T2 | 100 (14.8%) | 77 (19.7%) | 177 (16.6%) |  |
 T3 | 429 (63.6%) | 229 (58.6%) | 658 (61.8%) |  |
 T4 | 74 (11.0%) | 60 (15.3%) | 134 (12.6%) |  |
N stage | Â | Â | Â | 0.897 |
 N0 | 362 (52.5%) | 207 (51.6%) | 569 (52.2%) |  |
 N1 | 184 (26.7%) | 106 (26.4%) | 290 (26.6%) |  |
 N2 | 143 (20.8%) | 88 (21.9%) | 231 (21.2%) |  |
M stage | Â | Â | Â | 0.35 |
 M0 | 598 (86.5%) | 338 (84.3%) | 936 (85.7%) |  |
 M1 | 93 (13.5%) | 63 (15.7%) | 156 (14.3%) |  |
Lymphatic invasion | Â | Â | Â | 0.163 |
 Absent | 392 (56.8%) | 209 (52.2%) | 601 (55.1%) |  |
 Present | 298 (43.2%) | 191 (47.8%) | 489 (44.9%) |  |
Venous invasion | Â | Â | Â | 0.055 |
 Absent | 558 (81.0%) | 343 (85.8%) | 901 (82.7%) |  |
 Present | 131 (19.0%) | 57 (14.2%) | 188 (17.3%) |  |
Perineural invasion | Â | Â | Â | 0.123 |
 Absent | 537 (77.8%) | 294 (73.5%) | 831 (76.2%) |  |
 Present | 153 (22.2%) | 106 (26.5%) | 259 (23.8%) |  |
Differentiation | Â | Â | Â | 0.002 |
 Well/Moderate | 629 (94.7%) | 374 (98.7%) | 1003 (96.2%) |  |
 Poor | 35 (5.3%) | 5 (1.3%) | 40 (3.8%) |  |
Histology | Â | Â | Â | 0.008 |
 Non-mucinous adenocarcinoma | 657 (95.1%) | 364 (90.8%) | 1021 (93.5%) |  |
 Mucinous adenocarcinoma | 34 (4.9%) | 37 (9.2%) | 71 (6.5%) |  |
Recur | Â | Â | Â | 0.143 |
 Recur | 593 (85.8%) | 330 (82.3%) | 923 (84.5%) |  |
 Non-recur | 98 (14.2%) | 71 (17.7%) | 169 (15.5%) |  |
Expire | Â | Â | Â | 0.219 |
 Expire | 629 (91.0%) | 355 (88.5%) | 984 (90.1%) |  |
 Non- Expire | 62 (9.0%) | 46 (11.5%) | 108 (9.9%) |  |
Neoadjuvant Tx | Â | Â | Â | 0.217 |
 No | 605 (87.6%) | 364 (90.8%) | 969 (88.7%) |  |
 CTx | 31 (4.5%) | 10 (2.5%) | 41 (3.8%) |  |
 RT | 2 (0.3%) | 0 (0.0%) | 2 (0.2%) |  |
 CCRT | 53 (7.7%) | 27 (6.7%) | 80 (7.3%) |  |